Role of histone and transcription factor acetylation in diabetes pathogenesis

Diabetes/Metabolism Research and Reviews

Volumn 21, Issue 5, 2005, Pages 416-433

  Gray, Steven G ^a,b   De Meyts, Pierre ^a  

^a HAGEDORN RESEARCH INSTITUTE   (Denmark)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

Acetylation; Chromatin; Diabetes; Pathogenesis; Transciption factor

Indexed keywords

4 N ACETYLDINALINE; AMYLIN; BUTYRIC ACID; BUTYRIC ACID DERIVATIVE; CCAAT ENHANCER BINDING PROTEIN ALPHA; CONNEXIN 36; DEPSIPEPTIDE; FR 901288; GENE PRODUCT; GLUCOKINASE; GLUCOSE TRANSPORTER 4; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HOMEODOMAIN PROTEIN; LEPTIN; NEUROGENIC DIFFERENTIATION FACTOR; NICOTINAMIDE; NUCLEAR FACTOR I; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIVALOYLOXYMETHYL BUTYRATE; RESISTIN; SALICYLIC ACID DERIVATIVE; SIRTUIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION FACTOR; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ACETYLATION; CHROMATIN; CLINICAL TRIAL; CONFUSION; DIABETES MELLITUS; DIARRHEA; DYSPEPSIA; ENZYME ACTIVITY; FATIGUE; GENE TARGETING; HEART ARRHYTHMIA; HISTONE CODE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; LEUKOPENIA; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN MODIFICATION; REVIEW; SOLID TUMOR; SOMNOLENCE; SPINAL MUSCULAR ATROPHY; STOMACH PAIN; THROMBOCYTOPENIA; TRANSCRIPTION REGULATION; VISUAL IMPAIRMENT; VOMITING;

ACETYLATION; ACETYLTRANSFERASES; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HISTONES; HUMANS; INFLAMMATION; ISLETS OF LANGERHANS; MUTATION; NEURODEGENERATIVE DISEASES; TRANSCRIPTION FACTORS;

EID: 24944496184     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.559     Document Type: Review

References (246)

1. Donath MY, Halban PA. Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia 2004; 47: 581-589.
2. Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord 2003; 27: 49-52.
3. Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003; 27: 53-55.
4. Petersen KF, Dufour S, Befroy D, et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004; 350: 664-671.
5. De Meyts P. The diabetogenes concept of NIDDM. Adv Exp Med Biol 1993; 334: 89-100.
6. Kahn CR. Banting lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994; 43: 1066-1084.
7. Granner DK, O'Brien RM. Molecular physiology and genetics of NIDDM. Importance of metabolic staging. Diabetes Care 1992; 15: 369-395.
8. Hales CN, Barker DJ. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 1992; 35: 595-601.
9. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293: 1074-1080.
10. Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004; 338: 17-31.
11. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? Embo J 2000; 19: 1176-1179.
12. Yang XJ. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res 2004; 32: 959-976.
13. Gray SG, Teh BT. Histone acetylation/deacetylation and cancer: an "open" and "shut" case? Curr Mol Med 2001; 1: 401-429.
14. Gray SG, Ekstrom TJ. The human histone deacetylase family. Exp Cell Res 2001; 262: 75-83.
15. Gray SG. Histone acetyltransferases and histone deacetylases in gene regulation and as drug targets. In Progress in Oncology, Devita VT. Jr, Hellman S, Rosenberg SA (eds). Jones and Bartlett: Sudbury, 2004; 99-128.
16. Nerup J, Pociot F. A genomewide scan for type 1-diabetes susceptibility in Scandinavian families: identification of new loci with evidence of interactions. Am J Hum Genet 2001; 69: 1301-1313.
17. Xiang K, Wang Y, Zheng T, et al. Genome-wide search for type 2 diabetes/impaired glucose homeostasis susceptibility genes in the Chinese: significant linkage to chromosome 6q21-q23 and chromosome 1q21-q24. Diabetes 2004; 53: 228-234.
18. van Tilburg JH, Sandkuijl LA, Strengman E, et al. A genome-wide scan in type 2 diabetes mellitus provides independent replication of a susceptibility locus on 18p11 and suggests the existence of novel Loci on 2q12 and 19q13. J Clin Endocrinol Metab 2003; 88: 2223-2230.
19. Yamauchi T, Oike Y, Kamon J, et al. Increased insulin sensitivity despite lipodystrophy in Crebbp heterozygous mice. Nat Genet 2002; 30: 221-226.
20. Chakrabarti SK, Francis J, Ziesmann SM, et al. Covalent histone modifications underlie the developmental regulation of insulin gene transcription in pancreatic beta cells. J Biol Chem 2003; 278: 23 617-23 623.
21. Mosley AL, Ozcan S. Glucose regulates insulin gene transcription by hyperacetylation of histone h4. J Biol Chem 2003; 278: 19 660-19 666.
22. Bartoov-Shifman R, Hertz R, Wang H, et al. Activation of the insulin gene promoter through a direct effect of hepatocyte nuclear factor 4 alpha. J Biol Chem 2002; 277: 25 914-25 919.
23. Soutoglou E, Katrakili N, Talianidis I. Acetylation regulates transcription factor activity at multiple levels. Mol Cell 2000; 5: 745-751.
24. Roth U, Curth K, Unterman TG, et al. The transcription factors HIF-1 and HNF-4 and the coactivator p300 are involved in insulin-regulated glucokinase gene expression via the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 2004; 279: 2623-2631.
25. Massillon D, Arinze IJ, Xu C, et al. Regulation of glucose-6-phosphatase gene expression in cultured hepatocytes and H4IIE cells by short-chain fatty acids: role of hepatic nuclear factor-4alpha. J Biol Chem 2003; 278: 40 694-40 701.
26. Magenheim J, Hertz R, Berman I, et al. Negative autoregulation of HNF-4alpha gene expression by HNF-4alpha1. Biochem J 2005.
27. Pontoglio M, Faust DM, Doyen A, et al. Hepatocyte nuclear factor 1alpha gene inactivation impairs chromatin remodeling and demethylation of the phenylalanine hydroxylase gene. Mol Cell Biol 1997; 17: 4948-4956.
28. Soutoglou E, Papafotiou G, Katrakili N, et al. Transcriptional activation by hepatocyte nuclear factor-1 requires synergism between multiple coactivator proteins. J Biol Chem 2000; 275: 12 515-12 520.
29. Soutoglou E, Viollet B, Vaxillaire M, et al. Transcription factor-dependent regulation of CBP and P/CAF histone acetyltransferase activity. EMBO J 2001; 20: 1984-1992.
30. Kim KA, Kang K, Chi YI, et al. Identification and functional characterization of a novel mutation of hepatocyte nuclear factor-1alpha gene in a Korean family with MODY3. Diabetologia 2003; 46: 721-727.
31. Parrizas M, Maestro MA, Boj SF, et al. Hepatic nuclear factor 1-alpha directs nucleosomal hyperacetylation to its tissue-specific transcriptional targets. Mol Cell Biol 2001; 21: 3234-3243.
32. Ban N, Yamada Y, Someya Y, et al. Hepatocyte nuclear factor-1alpha recruits the transcriptional co-activator p300 on the GLUT2 gene promoter. Diabetes 2002; 51: 1409-1418.
33. Melloul D. Transcription factors in islet development and physiology: role of PDX-1 in beta-cell function. Ann N Y Acad Sci 2004; 1014: 28-37.
34. Chakrabarti SK, James JC, Mirmira RG. Quantitative assessment of gene targeting in vitro and in vivo by the pancreatic transcription factor, Pdx1. Importance of chromatin structure in directing promoter binding. J Biol Chem 2002; 277: 13 286-13 293.
35. Qiu Y, Guo M, Huang S, et al. Insulin gene transcription is mediated by interactions between the p300 coactivator and PDX-1, BETA2, and E47. Mol Cell Biol 2002; 22: 412-420.
36. Gerrish K, Van Velkinburgh JC, Stein R. Conserved transcriptional regulatory domains of the pdx-1 gene. Molecular Endocrinology 2004; 18: 533-548.
37. Stanojevic V, Habener JF, Thomas MK. Pancreas duodenum homeobox-1 transcriptional activation requires interactions with p300. Endocrinology 2004; 145: 2918-2928.
38. Kitanaka S, Miki Y, Hayashi Y, et al. Promoter-specific repression of hepatocyte nuclear factor (HNF)-1 beta and HNF-1 alpha transcriptional activity by an HNF-1 beta missense mutant associated with type 5 maturity-onset diabetes of the young with hepatic and biliary manifestations. J Clin Endocrinol Metab 2004; 89: 1369-1378.
39. Lindner TH, Njolstad PR, Horikawa Y, et al. A novel syndrome of diabetes mellitus, renal dysfunction and genital malformation associated with a partial deletion of the pseudo-POU domain of hepatocyte nuclear factor-1beta. Hum Mol Genet 1999; 8: 2001-2008.
40. Barbacci E, Chalkiadaki A, Masdeu C, et al. HNF1beta/TCF2 mutations impair transactivation potential through altered co-regulator recruitment. Hum Mol Genet 2004; 13: 3139-3149. Epub.
41. Malecki MT, Jhala US, Antonellis A, et al. Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. Nat Genet 1999; 23: 323-328.
42. Qiu Y, Sharma A, Stein R. p300 mediates transcriptional stimulation by the basic helix-loop-helix activators of the insulin gene. Mol Cell Biol 1998; 18: 2957-2964.
43. Sharma A, Moore M, Marcora E, et al. The NeuroD1/BETA2 sequences essential for insulin gene transcription colocalize with those necessary for neurogenesis and p300/CREB binding protein binding. Mol Cell Biol 1999; 19: 704-713.
44. Kim JY, Chu K, Kim HJ, et al. Orphan nuclear receptor small heterodimer partner, a novel corepressor for a basic helix-loop-helix transcription factor BETA2/neuroD. Mol Endocrinol 2004; 18: 776-790.
45. Qiu Y, Guo M, Huang S, et al. Acetylation of the BETA2 transcription factor by p300-associated factor is important in insulin gene expression. J Biol Chem 2004; 279: 9796-9802.
46. Lee CS, Sund NJ, Vatamaniuk MZ, et al. Foxa2 controls Pdx1 gene expression in pancreatic beta-cells in vivo. Diabetes 2002; 51: 2546-2551.
47. Lantz KA, Vatamaniuk MZ, Brestelli JE, et al. Foxa2 regulates multiple pathways of insulin secretion. J Clin Invest 2004; 114: 512-520.
48. Kulkarni RN, Jhala US, Winnay JN, et al. PDX-1 haploinsufficiency limits the compensatory islet hyperplasia that occurs in response to insulin resistance. J Clin Invest 2004; 114: 828-836.
49. Rausa FM, Tan Y, Costa RH. Association between hepatocyte nuclear factor 6 (HNF-6) and FoxA2 DNA binding domains stimulates FoxA2 transcriptional activity but inhibits HNF-6 DNA binding. Mol Cell Biol 2003; 23: 437-449.
50. Rausa FM, Hughes DE, Costa RH III. Stability of the hepatocyte nuclear factor 6 transcription factor requires acetylation by the CREB-binding protein coactivator. J Biol Chem 2004; 279: 43 070-43 076.
51. Jacquemin P, Lemaigre FP, Rousseau GG. The Onecut transcription factor HNF-6 (OC-1) is required for timely specification of the pancreas and acts upstream of Pdx-1 in the specification cascade. Dev Biol 2003; 258: 105-116.
52. Le Lay J, Matsuoka TA, Henderson E, et al. Identification of a novel PDX-1 binding site in the human insulin gene enhancer. J Biol Chem 2004; 279: 22 228-22 235.
53. Mosley AL, Ozcan S. The pancreatic duodenal homeobox-1 protein (Pdx-1) interacts with histone deacetylases Hdac-1 and Hdac-2 on low levels of glucose. J Biol Chem 2004; 279: 54 241-54 247.
54. Mosley AL, Corbett JA, Ozcan S. Glucose regulation of insulin gene expression requires the recruitment of p300 by the beta-cell-specific transcription factor Pdx-1. Mol Endocrinol 2004; 18: 2279-2290.
55. Boj SF, Parrizas M, Maestro MA, et al. A transcription factor regulatory circuit in differentiated pancreatic cells. Proc Natl Acad Sci USA 2001; 98: 14 481-14 486.
56. Ritz-Laser B, Mamin A, Brun T, et al. The zinc finger-containing transcription factor Gata-4 is expressed in the developing endocrine pancreas and activates glucagon gene expression. Mol Endocrinol 2005; 19: 759-770.
57. Cirillo LA, Lin FR, Cuesta I, et al. Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol Cell 2002; 9: 279-289.
58. Dai YS, Markham BE. p300 functions as a coactivator of transcription factor GATA-4. J Biol Chem 2001; 276: 37 178-37 185.
59. Cissell MA, Zhao L, Sussel L, et al. Transcription factor occupancy of the insulin gene in vivo. Evidence for direct regulation by Nkx2.2. J Biol Chem 2003; 278: 751-756.
60. Watada H, Scheel DW, Leung J, et al. Distinct gene expression programs function in progenitor and mature islet cells. J Biol Chem 2003; 278: 17 130-17 140.
61. White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 2002; 283: E413-E422.
62. Lin X, Taguchi A, Park S, et al. Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and diabetes. J Clin Invest 2004; 114: 908-916.
63. Kubota N, Terauchi Y, Tobe K, et al. Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. J Clin Invest 2004; 114: 917-927.
64. Shirakami A, Toyonaga T, Tsuruzoe K, et al. Heterozygous knockout of the IRS-1 gene in mice enhances obesity-linked insulin resistance: a possible model for the development of type 2 diabetes. J Endocrinol 2002; 174: 309-319.
65. Laustsen PG, Michael MD, Crute BE, et al. Lipoatrophic diabetes in Irs1(-/-)/Irs3(-/-) double knockout mice. Genes Dev 2002; 16: 3213-3222.
66. Araujo EP, Amaral ME, Filiputti E, et al. Restoration of insulin secretion in pancreatic islets of protein-deficient rats by reduced expression of insulin receptor substrate (IRS)-1 and IRS-2. J Endocrinol 2004; 181: 25-38.
67. Kaiser C, James SR. Acetylation of insulin receptor substrate-1 is permissive for tyrosine phosphorylation. BMC Biol 2004; 2: 23.
68. Lukinius A, Wilander E, Westermark GT, et al. Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets. Diabetologia 1989; 32: 240-244.
69. Wang ZL, Bennet WM, Ghatei MA, et al. Influence of islet amyloid polypeptide and the 8-37 fragment of islet amyloid polypeptide on insulin release from perifused rat islets. Diabetes 1993; 42: 330-335.
70. Furnsinn C, Leuvenink H, Roden M, et al. Islet amyloid polypeptide inhibits insulin secretion in conscious rats. Am J Physiol 1994; 267: E300-E305.
71. Akesson B, Panagiotidis G, Westermark P, et al. Islet amyloid polypeptide'inhibits glucagon release and exerts a dual action on insulin release from isolated islets. Regul Pept 2003; 111: 55-60.
72. Cluck MW, Murphy LO, Olson J, et al. Amylin gene expression mediated by cAMP/PKA and transcription factors HNF-1 and NFY. Mol Cell Endocrinol 2003; 210: 63-75.
73. Green J, Naot D, Cooper G. Hepatocyte nuclear factor 1 negatively regulates amylin gene expression. Biochem Biophys Res Commun 2003; 310: 464-469.
74. Shepherd LM, Campbell SC, Macfarlane WM. Transcriptional regulation of the IAPP gene in pancreatic beta-cells. Biochim Biophys Acta 2004; 1681: 28-37.
75. Park SH, Lee SR, Kim BC, et al. Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells. J Biol Chem 2002; 277: 5168-5174.
76. Currie RA. NF-Y is associated with the histone acetyltransferases GCN5 and P/CAF. J Biol Chem 1998; 273: 1430-1434.
77. Segretain D, Falk MM. Regulation of connexin biosynthesis, assembly, gap junction formation, and removal. Biochim Biophys Acta 2004; 1662: 3-21.
78. Calabrese A, Caton D, Meda P. Differentiating the effects of Cx36 and E-cadherin for proper insulin secretion of MIN6 cells. Exp Cell Res 2004; 294: 379-391.
79. Martin D, Tawadros T, Meylan L, et al. Critical role of the transcriptional repressor neuron-restrictive silencer factor in the specific control of connexin36 in insulin-producing cell lines. J Biol Chem 2003; 278: 53 082-53 089.
80. Chakrabarti SK, Mirmira RG. Transcription factors direct the development and function of pancreatic beta cells. Trends Endocrinol Metab 2003; 14: 78-84.
81. Vojtek AB, Taylor J, DeRuiter SL, et al. Akt regulates basic helix-loop-helix transcription factor-coactivator complex formation and activity during neuronal differentiation. Mol Cell Biol 2003; 23: 4417-4427.
82. Smith SB, Gasa R, Watada H, et al. Neurogenin3 and hepatic nuclear factor 1 cooperate in activating pancreatic expression of Pax4. J Biol Chem 2003; 278: 38 254-38 259.
83. Kemp DM, Lin JC, Habener JF. Regulation of Pax4 paired homeodomain gene by neuron-restrictive silencer factor. J Biol Chem 2003; 278: 35 057-35 062.
84. Huang Y, Myers SJ, Dingledine R. Transcriptional repression by REST: recruitment of Sin3A and histone deacetylase to neuronal genes. Nat Neurosci 1999; 2: 867-872.
85. Michelle Furtado L, Poon V, Klip A. GLUT4 activation: thoughts on possible mechanisms. Acta Physiol Scand 2003; 178: 287-296.
86. Moreno H, Serrano AL, Santalucia T, et al. Differential regulation of the muscle-specific GLUT4 enhancer in regenerating and adult skeletal muscle. J Biol Chem 2003; 278: 40 557-40 564.
87. Thai MV, Guruswamy S, Cao KT, et al. Myocyte enhancer factor 2 (MEF2)-binding site is required for GLUT4 gene expression in transgenic mice. Regulation of MEF2 DNA binding activity in insulin-deficient diabetes. J Biol Chem 1998; 273: 14 285-14 292.
88. Mora S, Pessin JE. The MEF2A isoform is required for striated muscle-specific expression of the insulin-responsive GLUT4 glucose transporter. J Biol Chem 2000; 275: 16 323-16 328.
89. Mora S, Yang C, Ryder JW, et al. The MEF2A and MEF2D isoforms are differentially regulated in muscle and adipose tissue during states of insulin deficiency. Endocrinology 2001; 142: 1999-2004.
90. Lu J, McKinsey TA, Nicol RL, et al. Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. Proc Natl Acad Sci USA 2000; 97: 4070-4075.
91. Dressel U, Bailey PJ, Wang SC, et al. A dynamic role for HDAC7 in MEF2-mediated muscle differentiation. J Biol Chem 2001; 276: 17 007-17 013.
92. Lu J, McKinsey TA, Zhang CL, et al. Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. Mol Cell 2000; 6: 233-244.
93. McKinsey TA, Zhang CL, Olson EN. Control of muscle development by dueling HATS and HDACs. Curr Opin Genet Dev 2001; 11: 497-504.
94. Rawson RB. The SREBP pathway-insights from Insigs and insects. Nat Rev Mol Cell Biol 2003; 4: 631-640.
95. Oliner JD, Andresen JM, Hansen SK, et al. SREBP transcriptional activity is mediated through an interaction with the CREB-binding protein. Genes Dev 1996; 10: 2903-2911.
96. Wagner BL, Valledor AF, Shao G, et al. Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression. Mol Cell Biol 2003; 23: 5780-5789.
97. Giandomenico V, Simonsson M, Gronroos E, et al. Coactivator-dependent acetylation stabilizes members of the SREBP family of transcription factors. Mol Cell Biol 2003; 23: 2587-2599.
98. Bennett MK, Osborne TF. Nutrient regulation of gene expression by the sterol regulatory element binding proteins: increased recruitment of gene-specific coregulatory factors and selective hyperacetylation of histone H3 in vivo. Proc Natl Acad Sci USA 2000; 97: 6340-6344.
99. Lane MD, Tang QQ, Jiang MS. Role of the CCAAT enhancer binding proteins (C/EBPs) in adipocyte differentiation. Biochem Biophys Res Commun 1999; 266: 677-683.
100. Wiper-Bergeron N, Wu D, Pope L, et al. Stimulation of preadipocyte differentiation by steroid through targeting of an HDAC1 complex. EMBO J 2003; 22: 2135-2145.
101. Hartman HB, Hu X, Tyler KX, et al. Mechanisms regulating adipocyte expression of resistin. J Biol Chem 2002; 277: 19 754-19 761.
102. Park SK, Oh SY, Lee MY, et al. CCAAT/enhancer binding protein and nuclear factor-Y regulate adiponectin gene expression in adipose tissue. Diabetes 2004; 53: 2757-2766.
103. Seo JB, Moon HM, Noh MJ, et al. Adipocyte determination- and differentiation-dependent factor 1/sterol regulatory element-binding protein 1c regulates mouse adiponectin expression. J Biol Chem 2004; 279: 22 108-22 117.
104. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications. Int J Obes Relat Metab Disord 2003; 27(Suppl 3): S41-S45.
105. Moller DE, Berger JP. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes Relat Metab Disord 2003; 27(Suppl 3): S17-S21.
106. Gurnell M, Savage DB, Chatterjee VK, et al. The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J Clin Endocrinol Metab 2003; 88: 2412-2421.
107. Zhou YT, Shimabukuro M, Wang MY, et al. Role of peroxisome proliferator-activated receptor alpha in disease of pancreatic beta cells. Proc Natl Acad Sci USA 1998; 95: 8898-8903.
108. Takahashi N, Kawada T, Yamamoto T, et al. Overexpression and ribozyme-mediated targeting of transcriptional coactivators CREB-binding protein and p300 revealed their indispensable roles in adipocyte differentiation through the regulation of peroxisome proliferator-activated receptor gamma. J Biol Chem 2002; 277: 16 906-16 912.
109. Fajas L, Egler V, Reiter R, et al. The retinoblastoma-histone deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation. Dev Cell 2002; 3: 903-910.
110. Mizukami J, Taniguchi T. The antidiabetic agent thiazolidinedione stimulates the interaction between PPAR gamma and CBP. Biochem Biophys Res Commun 1997; 240: 61-64.
111. Akiyama TE, Baumann CT, Sakai S, et al. Selective intranuclear redistribution of PPAR isoforms by RXR alpha. Mol Endocrinol 2002; 16: 707-721.
112. Herzig S, Hedrick S, Morantte I, et al. CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-gamma. Nature 2003; 426: 190-193.
113. Picard F, Kurtev M, Chung N, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004; 429: 771-776. Epub 2004 Jun 2002.
114. Cohen HY, Miller C, Bitterman KJ, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004; 305: 390-392. Epub 2004 Jun 2017.
115. Yamauchi T, Waki H, Kamon J, et al. Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 2001; 108: 1001-1013.
116. Puigserver P, Wu Z, Park CW, et al. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998; 92: 829-839.
117. Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 2003; 24: 78-90.
118. Yoon JC, Xu G, Deeney JT, et al. Suppression of beta cell energy metabolism and insulin release by PGC-1alpha. Dev Cell 2003; 5: 73-83.
119. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34: 267-273.
120. Puigserver P, Adelmant G, Wu Z, et al. Activation of PPARgamma coactivator-1 through transcription factor docking. Science 1999; 286: 1368-1371.
121. Wallberg AE, Yamamura S, Malik S, et al. Coordination of p300-mediated chromatin remodeling and TRAP/mediator function through coactivator PGC-1alpha. Mol Cell 2003; 12: 1137-1149.
122. Michael LF, Wu Z, Cheatham RB, et al. Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc Natl Acad Sci USA 2001; 98: 3820-3825.
123. Czubryt MP, McAnally J, Fishman GI, et al. Regulation of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) and mitochondrial function by MEF2 and HDAC5. Proc Natl Acad Sci USA 2003; 100: 1711-1716.
124. Nandi A, Kitamura Y, Kahn CR, et al. Mouse models of insulin resistance. Physiol Rev 2004; 84: 623-647.
125. Dowell P, Otto TC, Adi S, et al. Convergence of peroxisome proliferator-activated receptor gamma and Foxo1 signaling pathways. J Biol Chem 2003; 278: 45 485-45 491.
126. Puigserver P, Rhee J, Donovan J, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 2003; 423: 550-555.
127. Motta MC, Divecha N, Lemieux M, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004; 116: 551-563.
128. Brunet A, Sweeney LB, Sturgill JF, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303: 2011-2015.
129. Eizirik DL, Mandrup-Poulsen T. A choice of death-the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 2001; 44: 2115-2133.
130. Lamhamedi-Cherradi SE, Zheng S, Hilliard BA, et al. Transcriptional regulation of type I diabetes by NF-kappa B. J Immunol 2003; 171: 4886-4892.
131. Nusinzon I, Horvath CM. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc Natl Acad Sci USA 2003; 100: 14 742-14 747.
132. Paulson M, Pisharody S, Pan L, et al. Stat protein transactivation domains recruit p300/CBP through widely divergent sequences. J Biol Chem 1999; 274: 25 343-25 349.
133. Inoue H, Ogawa W, Ozaki M, et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med 2004; 10: 168-174.
134. Gao Q, Wolfgang MJ, Neschen S, et al. Disruption of neural signal transducer and activator of transcription 3 causes obesity, diabetes, infertility, and thermal dysregulation. Proc Natl Acad Sci USA 2004; 101: 4661-4666.
135. Yang Z, Chen M, Ellett JD, et al. Autoimmune diabetes is blocked in Stat4-deficient mice. J Autoimmun 2004; 22: 191-200.
136. Ghilardi N, Ziegler S, Wiestner A, et al. Defective STAT signaling by the leptin receptor in diabetic mice. Proc Natl Acad Sci USA 1996; 93: 6231-6235.
137. Yuan ZL, Guan YJ, Chatterjee D, et al. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005; 307: 269-273.
138. Wang R, Cherukuri P, Luo J. Activation of Stat3 sequence-specific DNA binding and transcription by p300/CBP mediated acetylation. J Biol Chem 2005; 280: 11 528-11 534.
139. Long J, Wang G, Matsuura I, et al. Activation of Smad transcriptional activity by protein inhibitor of activated STAT3 (PIAS3). Proc Natl Acad Sci USA 2004; 101: 99-104.
140. Xiao H, Chung J, Kao HY, et al. Tip60 is a co-repressor for STAT3. J Biol Chem 2003; 278: 11 197-11 204.
141. Peng Y, Laouar Y, Li MO, et al. TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci USA 2004; 101: 4572-4577.
142. O'Sullivan A, Chang HC, Yu Q, et al. STAT4 is required for interleukin-12-induced chromatin remodeling of the CD25 locus. J Biol Chem 2004; 279: 7339-7345.
143. Arora T, Liu B, He H, et al. PIASx is a transcriptional co-repressor of signal transducer and activator of transcription 4. J Biol Chem 2003; 278: 21 327-21 330.
144. Gewinner C, Hart G, Zachara N, et al. The coactivator of transcription CREB-binding protein interacts preferentially with the glycosylated form of Stat5. J Biol Chem 2004; 279: 3563-3572.
145. Litterst CM, Kliem S, Marilley D, et al. NCoA-1/SRC-1 is an essential coactivator of STAT5 that binds to the FDL motif in the alpha-helical region of the STAT5 transactivation domain. J Biol Chem 2003; 278: 45 340-45 351.
146. Pfitzner E, Jahne R, Wissler M, et al. p300/CREB-binding protein enhances the prolactin-mediated transcriptional induction through direct interaction with the transactivation domain of Stat5, but does not participate in the Stat5-mediated suppression of the glucocorticoid response. Mol Endocrinol 1998; 12: 1582-1593.
147. Nakajima H, Brindle PK, Handa M, et al. Functional interaction of STAT5 and nuclear receptor co-repressor SMRT: implications in negative regulation of STAT5-dependent transcription. Embo J 2001; 20: 6836-6844.
148. Xu M, Nie L, Kim SH, et al. STAT5-induced Id-1 transcription involves recruitment of HDAC1 and deacetylation of C/EBPbeta. Embo J 2003; 22: 893-904.
149. Ling L, Lobie PE. RhoA/ROCK activation by growth hormone abrogates p300/histone deacetylase 6 repression of Stat5-mediated transcription. J Biol Chem 2004; 279: 32 737-32 750.
150. Gingras S, Simard J, Groner B, et al. p300/CBP is required for transcriptional induction by interleukin-4 and interacts with Stat6. Nucleic Acids Res 1999; 27: 2722-2729.
151. McDonald C, Reich NC. Cooperation of the transcriptional coactivators CBP and p300 with Stat6. J Interferon Cytokine Res 1999; 19: 711-722.
152. Litterst CM, Pfitzner E. Transcriptional activation by STAT6 requires the direct interaction with NCoA-1. J Biol Chem 2001; 276: 45 713-45 721.
153. Valineva T, Yang J, Palovuori R, et al. The transcriptional coactivator protein p100 recruits HAT activity to STAT6 and mediates interaction between CBP and STAT6. J Biol Chem 2005; 280: 14 989-14 996.
154. Shankaranarayanan P, Chaitidis P, Kuhn H, et al. Acetylation by histone acetyltransferase CREB-binding protein/p300 of STAT6 is required for transcriptional activation of the 15-lipoxygenase-1 gene. J Biol Chem 2001; 276: 42 753-42 760.
155. Natarajan R, Nadler JL. Lipoxygenases and lipid signaling in vascular cells in diabetes. Front Biosci 2003; 8: s783-s795.
156. Ellerman K, Wrobleski M, Rabinovitch A, et al. Natural killer cell depletion and diabetes mellitus in the BB/Wor rat (revisited). Diabetologia 1993; 36: 596-601.
157. Poirot L, Benoist C, Mathis D. Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity. Proc Natl Acad Sci USA 2004; 101: 8102-8107.
158. Lee IF, Qin H, Trudeau J, et al. Regulation of autoimmune diabetes by complete Freund's adjuvant is mediated by NK cells. J Immunol 2004; 172: 937-942.
159. Lee PT, Putnam A, Benlagha K, et al. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 2002; 110: 793-800.
160. Kukreja A, Cost G, Marker J, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002; 109: 131-140.
161. Hohmeier HE, Tran VV, Chen G, et al. Inflammatory mechanisms in diabetes: lessons from the beta-cell. Int J Obes Relat Metab Disord 2003; 27(Suppl 3): S12-S16.
162. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
163. Lazar MA. How obesity causes diabetes: not a tall tale. Science 2005; 307: 373-375.
164. Van den Berghe G. How does blood glucose control with insulin save lives in intensive care? J Clin Invest 2004; 114: 1187-1195.
165. Cosentino F, Egidy Assenza G. Diabetes and Inflammation. Herz 2004; 29: 749-759.
166. Sjoholm A, Nystrom T. Endothelial inflammation in insulin resistance. Lancet 2005; 365: 610-612.
167. Dandona P, Aljada A, Chaudhuri A, et al. Endothelial dysfunction, inflammation and diabetes. Rev Endocr Metab Disord 2004; 5: 189-197.
168. Fonseca V, Desouza C, Asnani S, et al. Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev 2004; 25: 153-175.
169. Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005; 11: 191-198.
170. Gerritsen ME, Williams AJ, Neish AS, et al. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci USA 1997; 94: 2927-2932.
171. Perkins ND, Felzien LK, Betts JC, et al. Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science 1997; 275: 523-527.
172. Wadgaonkar R, Phelps KM, Haque Z, et al. CREB-binding protein is a nuclear integrator of nuclear factor-kappaB and p53 signaling. J Biol Chem 1999; 274: 1879-1882.
173. Na SY, Lee SK, Han SJ, et al. Steroid receptor coactivator-1 interacts with the p50 subunit and coactivatos nuclear factor kappaB-mediated transactivations. J Biol Chem 1998; 273: 10831-10834.
174. Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. Embo J 2004; 23: 2369-2380.
175. Hoberg JE, Yeung F, Mayo MW. SMRT derepression by the IkappaB kinase alpha: a prerequisite to NF-kappaB transcription and survival. Mol Cell 2004; 16: 245-255.
176. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7.
177. Esposito K, Nappo F, Giugliano F, et al. Cytokine milieu tends toward inflammation in type 2 diabetes. Diabetes Care 2003; 26: 1647.
178. Vanden Berghe W, De Bosscher K, Boone E, et al. The nuclear factor-kappaB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter. J Biol Chem 1999; 274: 32091-32098.
179. Ohara-Imaizumi M, Cardozo AK, Kikuta T, et al. The cytokine interleukin-1beta reduces the docking and fusion of insulin granules in pancreatic beta-cells, preferentially decreasing the first phase of exocytosis. J Biol Chem 2004; 279: 41271-41274.
180. Papaccio G, Graziano A, d'Aquino R, et al. A biphasic role of nuclear transcription factor (NF)-kappaB in the islet beta-cell apoptosis induced by interleukin (IL)-1beta. J Cell Physiol 2005; 204: 124-130.
181. Ito K, Hanazawa T, Tomita K, et al. Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration. Biochem Biophys Res Commun 2004; 315: 240-245.
182. Reddy P, Maeda Y, Hotary K, et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 2004; 101: 3921-3926.
183. Lee SK, Kim JH, Lee YC, et al. Silencing mediator of retinoic acid and thyroid hormone receptors, as a novel transcriptional corepressor molecule of activating protein-1, nuclear factor-kappaB, and serum response factor. J Biol Chem 2000; 275: 12470-12474.
184. Ashburner BP, Westerheide SD, Baldwin AS Jr. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 2001; 21: 7065-7077.
185. Kiernan R, Bres V, Ng RW, et al. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem 2003; 278: 2758-2766.
186. Rocha S, Martin AM, Meek DW, et al. p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1. Mol Cell Biol 2003; 23: 4713-4727.
187. Perissi V, Aggarwal A, Glass CK, et al. A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell 2004; 116: 511-526.
188. Schlezinger JJ, Jensen BA, Mann KK, et al. Peroxisome proliferator-activated receptor gamma-mediated NF-kappa B activation and apoptosis in pre-B cells. J Immunol 2002; 169: 6831-6841.
189. Miao F, Gonzalo IG, Lanting L, et al. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J Biol Chem 2004; 279: 18091-18097.
190. Yang Z, Chen M, Carter JD, et al. Inflammation blockade improves pancreatic islet function. Transplant Proc 2004; 36: 2864-2865.
191. Striffler JS, Nadler JL. Lisofylline, a novel anti-inflammatory agent, enhances glucose-stimulated insulin secretion in vivo and in vitro: studies in prediabetic and normal rats. Metabolism 2004; 53: 290-296.
192. George CL, Fantuzzi G, Bursten S, et al. Effects of lisofylline on hyperoxia-induced lung injury. Am J Physiol 1999; 276: L776-L785.
193. Bursten S, Weeks R, West J, et al. Potential role for phosphatidic acid in mediating the inflammatory responses to TNF alpha and IL-1 beta. Circ Shock 1994; 44: 14-29.
194. Warren S, Warren KG. Multiple sclerosis and associated diseases: a relationship to diabetes mellitus. Can J Neurol Sci 1981; 8: 35-39.
195. Wertman E, Zilber N, Abramsky O. An association between multiple sclerosis and type I diabetes mellitus. J Neurol 1992; 239: 43-45.
196. Marrosu MG, Cocco E, Lai M, et al. Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study. Lancet 2002; 359: 1461-1465.
197. Dorman JS, Steenkiste AR, Burke JP, et al. Type 1 diabetes and multiple sclerosis: together at last. Diabetes Care 2003; 26: 3192-3193.
198. Dasgupta S, Zhou Y, Jana M, et al. Sodium phenylacetate inhibits adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice at multiple steps. J Immunol 2003; 170: 3874-3882.
199. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J Mol Med 2004; 82: 510-529. Epub 2004 Jun 2003.
200. Andreassen OA, Dedeoglu A, Stanojevic V, et al. Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiol Dis 2002; 11: 410-424.
201. Steffan JS, Bodai L, Pallos J, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001; 413: 739-743.
202. Hockly E, Richon VM, Woodman B, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 2003; 100: 2041-2046.
203. Ferrante RJ, Kubilus JK, Lee J, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 2003; 23: 9418-9427.
204. Powers AC, Philippe J, Hermann H, et al. Sodium butyrate increases glucagon and insulin gene expression by recruiting immunocytochemically negative cells to produce hormone. Diabetes 1988; 37: 1405-1410.
205. Bouckenooghe T, Vandewalle B, Lukowiak B, et al. Modulation of specific beta cell gene (re)expression during in vitro expansion of human pancreatic islet cells. Cell Transplant 2003; 12: 799-807.
206. Shamblott MJ, Clark GO. Cell therapies for type 1 diabetes mellitus. Expert Opin Biol Ther 2004; 4: 269-277.
207. Lee JH, Hart SR, Skalnik DG. Histone deacetylase activity is required for embryonic stem cell differentiation. Genesis 2004; 38: 32-38.
208. Lumelsky N, Blondel O, Laeng P, et al. Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science 2001; 292: 1389-1394.
209. Schein PS, Cooney DA, Vernon ML. The use of nicotinamide to modify the toxicity of streptozotocin diabetes without loss of antitumor activity. Cancer Res 1967; 27: 2324-2332.
210. Stauffacher W, Burr I, Gutzeit A, et al. Streptozotocin diabetes: time course of irreversible B-cell damage; further observations on prevention by nicotinamide. Proc Soc Exp Biol Med 1970; 133: 194-200.
211. Sandler S, Andersson A, Korsgren O, et al. Tissue culture of human fetal pancreas. Effects of nicotinamide on insulin production and formation of isletlike cell clusters. Diabetes 1989; 38(Suppl 1): 168-171.
212. Korsgren O, Andersson A, Sandler S. Pretreatment of fetal porcine pancreas in culture with nicotinamide accelerates reversal of diabetes after transplantation to nude mice. Surgery 1993; 113: 205-214.
213. Gale EA, Bingley PJ, Emmett CL, et al. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004; 363: 925-931.
214. Liu HK, Green BD, Flatt PR, et al. Effects of long-term exposure to nicotinamide and sodium butyrate on growth, viability, and the function of clonal insulin secreting cells. Endocr Res 2004; 30: 61-68.
215. Jackson MD, Schmidt MT, Oppenheimer NJ, et al. Mechanism of nicotinamide inhibition and transglycosidation by Sir2 histone/protein deacetylases. J Biol Chem 2003; 278: 50985-50998.
216. Perseghin G, Petersen K, Shulman GI. Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord 2003; 27(Suppl 3): S6-11.
217. Pinckard RN, Hawkins D, Farr RS. In vitro acetylation of plasma proteins, enzymes and DNA by aspirin. Nature 1968; 219: 68-69.
218. Zeender E, Maedler K, Bosco D, et al. Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta. J Clin Endocrinol Metab 2004; 89: 5059-5066.
219. Lagace DC, Nachtigal MW. Inhibition of histone deacetylase activity by valproic acid blocks adipogenesis. J Biol Chem 2004; 279: 18851-18860.
220. Lagace DC, McLeod RS, Nachtigal MW. Valproic acid inhibits leptin secretion and reduces leptin messenger ribonucleic acid levels in adipocytes. Endocrinology 2004; 145: 5493-5503.
221. Takigawa-Imamura H, Sekine T, Murata M, et al. Stimulation of glucose uptake in muscle cells by prolonged treatment with scriptide, a histone deacetylase inhibitor. Biosci Biotechnol Biochem 2003; 67: 1499-1506.
222. Choi JH, Oh SW, Kang MS, et al. Trichostatin A attenuates airway inflammation in mouse asthma model. Clin Exp Allergy 2005; 35: 89-96.
223. Mishra N, Reilly CM, Brown DR, et al. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 2003; 111: 539-552.
224. Nambiar MP, Warke VG, Fisher CU, et al. Effect of trichostatin A on human T cells resembles signaling abnormalities in T cells of patients with systemic lupus erythematosus: a new mechanism for TCR zeta chain deficiency and abnormal signaling. J Cell Biochem 2002; 85: 459-469.
225. Mishra N, Brown DR, Olorenshaw IM, et al. Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells. Proc Natl Acad Sci USA 2001; 98: 2628-2633.
226. Chung YL, Lee MY, Wang AJ, et al. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 2003; 8: 707-717.
227. Liu WS, Huang Y, Zhang ZR. Synthesis and characterization of the tumor targeting mitoxantrone-insulin conjugate. Arch Pharm Res 2003; 26: 892-897.
228. Drummond DC, Noble CO, Kirpotin DB, et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005; 45: 495-528.
229. McLaughlin F, La Thangue NB. Histone deacetylase inhibitors open new doors in cancer therapy. Biochem Pharmacol 2004; 68: 1139-1144.
230. Gilbert J, Baker SD, Bowling MK, et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001; 7: 2292-2300.
231. Carducci MA, Gilbert J, Bowling MK, et al. A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 2001; 7: 3047-3055.
232. Gore SD, Weng LJ, Zhai S, et al. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 2001; 7: 2330-2339.
233. Gore SD, Weng LJ, Figg WD, et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 2002; 8: 963-970.
234. Mercuri E, Bertini E, Messina S, et al. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord 2004; 14: 130-135.
235. Brahe C, Vitali T, Tiziano FD, et al. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet 2005; 13: 256-259.
236. Patnaik A, Rowinsky EK, Villalona MA, et al. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin Cancer Res 2002; 8: 2142-2148.
237. Reid T, Valone F, Lipera W, et al. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 2004; 45: 381-386.
238. Prakash S, Foster BJ, Meyer M, et al. Chronic oral administration of CI-994: a phase 1 study. Invest New Drugs 2001; 19: 1-11.
239. Nemunaitis JJ, Orr D, Eager R, et al. Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer. Cancer J 2003; 9: 58-66.
240. Undevia SD, Kindler HL, Janisch L, et al. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol 2004; 15: 1705-1711.
241. Pauer LR, Olivares J, Cunningham C, et al. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest 2004; 22: 886-896.
242. Marshall JL, Rizvi N, Kauh J, et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2002; 2: 325-332.
243. Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630 176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8: 718-728.
244. Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003; 9: 3578-3588.
245. Monneret C. Histone deacetylase inhibitors. Eur J Med Chem 2005; 40: 1-13.
246. Garber K. Purchase of Aton spotlights HDAC inhibitors. Nat Biotechnol 2004; 22: 364-365.